Form4insider filings, from the source

SEC Form 4 · accession 0001209191-19-014941

Atara Biotherapeutics, Inc. · ATRA

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Period of report
Feb 27, 2019
Accepted (ET)
Mar 1, 2019 · 4:09 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001604464

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockFeb 27, 2019M25,000$25.15A32,590D
Common StockFeb 27, 2019M10,500$24.05A43,090D
Common StockFeb 27, 2019M5,500$15.08A48,590D
Common StockFeb 27, 2019M21,500$13.20A70,090D
Common StockF1Feb 28, 2019S62,590$36.07D7,500D
Common Stockholding———4,000IHeld by the Joel S. Marcus and Barbara A. Marcus Family Trust
Common StockF2holding———908,355ISee footnote

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Non-Qualified Stock Option (Right to Buy)F3$25.15Feb 27, 2019M25,000D—Jan 16, 2022Common Stock25,0000D
Non-Qualified Stock Option (Right to Buy)F3$24.05Feb 27, 2019M10,500D—Jan 4, 2023Common Stock10,5000D
Non-Qualified Stock Option (Right to Buy)F3$15.08Feb 27, 2019M5,500D—Jan 3, 2024Common Stock5,5000D
Non-Qualified Stock Option (Right to Buy)F3$13.20Feb 27, 2019M21,500D—Jun 8, 2024Common Stock21,5000D

Explanation of responses